(RTTNews) - While reporting financial results for the fourth quarter on Wednesday, drug major Johnson & Johnson (JNJ) initiated its adjusted earnings and sales guidance for the full-year 2026.
For fiscal 2026, the company now projects adjusted earnings in a range of $11.43 to $11.63 per share and adjusted operational earnings in a range of $11.28 to $11.48 per share on sales between $100 billion and $101 billion as well as operational sales between $99.5 billion and $100.5 billion, with adjusted operational sales growth of 5.4 to 6.4 percent.
On average, analysts polled expect the company to report earnings of $11.49 per share on sales of $98.77 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
